Matthew L. Meyerson
Company: Dana-Farber / Harvard Cancer Center
Job title: Director & Professor - Pathology, Medical Oncology & Center Cancer Genome Discovery
Seminars:
Breaking Industry Barriers: Discovering BAY2927088, Novel Inhibitor of ERBB2 Mutants in NSCLC 1:30 pm
Unpacking challenges of mutant-selective kinase inhibition: targeting EGFR/ERBB2 exon 20 insertion mutants Evaluating biochemical and cellular approaches to developing inhibitors for untargetable mutant TYK Revealing clinical data on selectivity for ERBB2 exon 20 insertion mutants in NSCLCRead more
day: Conference Day One